Edwards Lifesciences weekly recap highlights TAVR growth, PASCAL approval
Edwards Lifesciences projects mid- to high-single-digit durable TAVR growth; coverage shifts and rolling approvals/launches including PASCAL tricuspid and EVOQUE expansion.
Edwards Lifesciences projects mid- to high-single-digit durable TAVR growth; coverage shifts and rolling approvals/launches including PASCAL tricuspid and EVOQUE expansion.